Venetoclax Combined With Azactidine in the Treatment of ALAL — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Venetoclax Combined With Azactidine in the Treatment of ALAL — Stella

Recruiting

Back to Acute Leukemia of Ambiguous Lineage trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

The First Affliated Hospital of Soochow University, Suzhou

Key details

Phase

Safety & dosing

Sponsor

Sheng-Li Xue, MD

Collaborators

Jining Medical University, The Second People's Hospital of Huai'an

Enrollment target

~23 participants

Started

July 2023

Primary completion

March 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

15 Years and older

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov